Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb;81(2):290-300.
doi: 10.1111/bcp.12805. Epub 2016 Jan 27.

Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy

Lars-Erik Broksoe Kyhl  1 , Shen Li  2 , Kirstine Ullitz Faerch  1 , Birgitte Soegaard  1 , Frank Larsen  1 , Johan Areberg  1
Affiliations

Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy

Lars-Erik Broksoe Kyhl et al. Br J Clin Pharmacol. 2016 Feb.

Abstract

Aims: The aims of this study were to develop a population pharmacokinetic (PK) model to describe the PK of nalmefene in healthy subjects and to relate the exposure of nalmefene to the μ-opioid receptor occupancy by simulations in the target population.

Methods: Data from nine phase I studies (243 subjects) with extensive blood sampling were pooled and used for the population PK model building. Data from four other phase I studies (85 subjects) were pooled and used as an external validation dataset. Eight subjects from an imaging study contributed occupancy data and the pharmacokinetic/pharmacodynamic (PK/PD) relationship was modelled. Combining the population PK model and the PK/PD relationship enabled simulations to predict μ-opioid occupancy.

Results: A two compartment model with first order absorption best described the nalmefene PK data. The typical subject in the population was estimated to have a systemic clearance of 60.4 l h(-1) and a central volume of distribution of 266 l. Absolute oral bioavailability was estimated to 41% without food intake and with food about 53%. Simulation of the μ-opioid receptor occupancy shows that the 95% confidence bound is within or above 60-90% occupancy for up to 22-24 h after a single dose of 20 mg nalmefene.

Conclusions: A robust population PK model for nalmefene was developed. Based on the concentration-occupancy model the μ-opioid receptor occupancy after a single 20 mg dose of nalmefene is predicted to be above the target therapeutic occupancy for about 24 h in about 95% of the target population.

Keywords: alcohol dependence; healthy subjects; nalmefene; opioid antagonist; pharmacodynamics; pharmacokinetics.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Goodness‐of‐fit plots for the final population pharmacokinetic model for nalmefene
Figure 2
Figure 2
Visual predictive check (VPC) plots for the validation dataset for A) day 1 and B) day 5 of dosing. Full lines show median and percentiles (2.5% and 97.5%) of simulated data, while dotted lines show median and percentiles (2.5% and 97.5%) of observed data
Figure 3
Figure 3
Normalized prediction distribution error (NPDE) plots for the validation dataset
Figure 4
Figure 4
Plasma concentration of nalmefene vs. observed and fitted μ‐opioid receptor occupancy
Figure 5
Figure 5
A) Simulated plasma concentration curves of nalmefene and B) simulated duration of μ‐opioid receptor occupancy after a single dose of 20 mg in fed state with 95% confidence bounds
See this image and copyright information in PMC

References

    1. Bart G, Schluger JH, Borg L, Ho A, Bidlack JM, Kreek MJ. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacology 2005; 30: 2254–62. - PubMed
    1. Guerrero M, Urbano M, Brown SJ, Cayanan C, Ferguson J, Cameron M, Devi LA, Roberts E, Rosen H. Optimization and characterization of an opioid kappa receptor (OPRK1) antagonist. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010. 2013 Apr 15 [updated 2013 Nov 14]. - PubMed
    1. EMA . Selincro: EPAR prodution information. Annex I – summary of product characteristics. Available at www.ema.europa.eu [homepage on internet] (last accessed 2 October 2015).
    1. Gual A, He Y, Torup L, van den Brick W, Mann K. A randomised, double‐blind, placebo‐controlled, efficacy study of nalmefene, as‐needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol 2013; 23: 1432–42. - PubMed
    1. Mann K, Bladström A, Torup L, Gual A, van den Brink W. Extending the treatment options in alcohol dependence: a randomized controlled study of as‐needed nalmefene. Biol Psychiatry 2013; 73: 706–13. - PubMed

Publication types

MeSH terms